Picture 1 of 1

Stock photo

A Review of Pre-exposure Prophylaxis (PrEP) for HIV Prevention: Truvada, a Pi… - Picture 1 of 1

Pre-Exposure Prophylaxis for HIV Prevention by Moffat Joel Matyanga Celia (2014, Trade Paperback)

AMA - BOOKS (4285)

96.6% positive Feedback

Price:

US $562.00

Approximately£423.22

+ $32.26 postage

Estimated delivery Tue, 19 Aug - Wed, 27 Aug

Returns:

30 days return. Buyer pays for return postage. If you use an eBay delivery label, it will be deducted from your refund amount.

Condition:

Good

This is the first ever FDA drug approval for HIV prevention. In addition, it describes the safety profile of Truvada (R) for PrEP. Illustrated Yes. Target Audience Trade. Author Moffat Joel Matyanga Celia.

About this product

Product Identifiers

PublisherLAP Gmbh & Company KG

ISBN-103659666696

ISBN-139783659666698

eBay Product ID (ePID)246156968

Product Key Features

Number of Pages52 Pages

LanguageEnglish

Publication NamePre-Exposure Prophylaxis for Hiv Prevention

SubjectClinical Medicine

Publication Year2014

TypeTextbook

Subject AreaMedical

AuthorMoffat Joel Matyanga Celia

FormatTrade Paperback

Dimensions

Item Height0.1 in

Item Weight3.2 Oz

Item Length9 in

Item Width6 in

Additional Product Features

Intended AudienceTrade

IllustratedYes

SynopsisThe Food and Drug Administration (FDA) approved and licensed a drug to prevent HIV acquisition in 2012. This is the first ever FDA drug approval for HIV prevention. Tenofovir combined with emtricitabine (Truvada (R)) was licensed to be used in conjunction with other HIV prevention methods by HIV negative people at high risk of HIV acquisition. This novel method of HIV prevention is termed HIV pre - exposure prophylaxis (PrEP). Whilst the use of PrEP has been implemented in some countries, this is still a new method and several countries are to still implement PrEP. The use of PrEP will go a long way in globally controlling the ever surging rise of the AIDS epidemic. This book, therefore provides an extensive description of PrEP from basic information to scientific studies. It offers a concise and comprehensive description of how Truvada (R) was tested for safety and efficacy in both animals and humans. In addition, it describes the safety profile of Truvada (R) for PrEP. This book is especially useful to clinicians, medical personnel, pharmacists, regulatory authorities and even consumers who may require more information on this novel and effective drug to prevent HIV., The Food and Drug Administration (FDA) approved and licensed a drug to prevent HIV acquisition in 2012. This is the first ever FDA drug approval for HIV prevention. Tenofovir combined with emtricitabine (Truvada (r)) was licensed to be used in conjunction with other HIV prevention methods by HIV negative people at high risk of HIV acquisition. This novel method of HIV prevention is termed HIV pre - exposure prophylaxis (PrEP). Whilst the use of PrEP has been implemented in some countries, this is still a new method and several countries are to still implement PrEP. The use of PrEP will go a long way in globally controlling the ever surging rise of the AIDS epidemic. This book, therefore provides an extensive description of PrEP from basic information to scientific studies. It offers a concise and comprehensive description of how Truvada (r) was tested for safety and efficacy in both animals and humans. In addition, it describes the safety profile of Truvada (r) for PrEP. This book is especially useful to clinicians, medical personnel, pharmacists, regulatory authorities and even consumers who may require more information on this novel and effective drug to preven